Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece;Validation du questionnaire finlandais calculant un score de risque de diabète (FINDRISC) pour le dépistage du diabète de type 2, des anomalies de la glycorégulation et du syndrome métabolique en Grèce

Diabetes and Metabolism

Volumn 37, Issue 2, 2011, Pages 144-151

  Makrilakis, K ^a   Liatis, S ^a   Grammatikou, S ^a   Perrea, D ^a   Stathi, C ^a   Tsiligros, P ^a   Katsilambros, N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Diabetes prevention; Diabetes screening; Diagnosis; FINDRISC questionnaire; Greece; Impaired fasting glucose; Impaired glucose tolerance; Type 2 diabetes

Indexed keywords

ADULT; AGED; ARTICLE; CITY; CLINICAL EVALUATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FINNISH DIABETES RISK SCORE QUESTIONNAIRE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GREECE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREDICTION; PREDICTIVE VALUE; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; SAMPLE; SCREENING; SENSITIVITY ANALYSIS; SUBURBAN AREA; VALIDATION PROCESS;

ADULT; AGED; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; FINLAND; GLUCOSE METABOLISM DISORDERS; GLUCOSE TOLERANCE TEST; GREECE; HUMANS; MALE; MASS SCREENING; METABOLIC SYNDROME X; MIDDLE AGED; QUESTIONNAIRES; RISK FACTORS; ROC CURVE;

EID: 79955056575     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.09.006     Document Type: Article

References (40)

1. Cowie C.C., Rust K.F., Ford E.S., Eberhardt M.S., Byrd-Holt D.D., Li C., et al. Full accounting of diabetes and pre-diabetes in the U.S. Population in 1988-1994 and 2005-2006. Diabetes Care 2009, 32:287-294.
2. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003, 46:3-19.
3. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
4. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
5. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the stop-NIDDM randomized trial. Lancet 2002, 359:2072-2077.
6. Gerstein H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006, 368:1096-1105.
7. Paulweber B., Valensi P., Lindstrom J., Lalic N.M., Greaves C.J., McKee M., et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res 2010, 42(Suppl 1):S3-S36.
8. Waugh N., Scotland G., McNamee P., Gillett M., Brennan A., Goyder E., et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 2007, 11(iii-iv, ix-xi):1-125.
9. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl 1):S62-S69.
10. Haffner S.M., Stern M.P., Hazuda H.P., Mitchell B.D., Patterson J.K. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA 1990, 263:2893-2898.
11. Kohli P., Greenland P. Role of the metabolic syndrome in risk assessment for coronary heart disease. JAMA 2006, 295:819-821.
12. Lindstrom J., Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003, 26:725-731.
13. Glumer C., Carstensen B., Sandbaek A., Lauritzen T., Jorgensen T., Borch-Johnsen K. A Danish diabetes risk score for targeted screening: the inter99 study. Diabetes Care 2004, 27:727-733.
14. Baan C.A., Ruige J.B., Stolk R.P., Witteman J.C., Dekker J.M., Heine R.J., et al. Performance of a predictive model to identify undiagnosed diabetes in a health care setting. Diabetes Care 1999, 22:213-219.
15. Stern M.P., Williams K., Haffner S.M. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?. Ann Intern Med 2002, 136:575-581.
16. Griffin S.J., Little P.S., Hales C.N., Kinmonth A.L., Wareham N.J. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev 2000, 16:164-171.
17. Colagiuri S., Hussain Z., Zimmet P., Cameron A., Shaw J. Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience. Diabetes Care 2004, 27:367-371.
18. Herman W.H., Smith P.J., Thompson T.J., Engelgau M.M., Aubert R.E. A new and simple questionnaire to identify people at increased risk for undiagnosed diabetes. Diabetes Care 1995, 18:38238-38247.
19. Kanaya A.M., Wassel Fyr C.L., de Rekeneire N., Shorr R.I., Schwartz A.V., Goodpaster B.H., et al. Predicting the development of diabetes in older adults: the derivation and validation of a prediction rule. Diabetes Care 2005, 28:404-408.
20. Heikes K.E., Eddy D.M., Arondekar B., Schlessinger L. Diabetes risk calculator: a simple tool for detecting undiagnosed diabetes and pre-diabetes. Diabetes Care 2008, 31:1040-1045.
21. Balkau B., Lange C., Fezeu L., Tichet J., de Lauzon-Guillain B., Czernichow S., et al. Predicting diabetes: clinical, biological, and genetic approaches: data from the epidemiological study on the insulin resistance syndrome (Desir). Diabetes Care 2008, 31:2056-2061.
22. Saaristo T., Peltonen M., Lindstrom J., Saarikoski L., Sundvall J., Eriksson J.G., et al. Cross-sectional evaluation of the Finnish diabetes risk score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diab Vasc Dis Res 2005, 2:67-72.
23. Franciosi M., De Berardis G, Rossi M.C., Sacco M., Belfiglio M., Pellegrini F., et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (impaired glucose tolerance and long-term outcomes observational) study. Diabetes Care 2005, 28:1187-1194.
24. Bergmann A., Li J., Wang L., Schulze J., Bornstein S.R., Schwarz P.E. A simplified Finnish diabetes risk score to predict type 2 diabetes risk and disease evolution in a German population. Horm Metab Res 2007, 39:677-682.
25. Rathmann W., Martin S., Haastert B., Icks A., Holle R., Lowel H., et al. Performance of screening questionnaires and risk scores for undiagnosed diabetes: the KORA survey 2000. Arch Intern Med 2005, 165:436-441.
26. Witte D.R., Shipley M.J., Marmot M.G., Brunner E.J. Performance of existing risk scores in screening for undiagnosed diabetes: an external validation study. Diabet Med 2010, 27:46-53.
27. Lin J.W., Chang Y.C., Li H.Y., Chien Y.F., Wu M.Y., Tsai R.Y., et al. Cross-sectional validation of diabetes risk scores for predicting diabetes, metabolic syndrome, and chronic kidney disease in Taiwanese. Diabetes Care 2009, 32:2294-2296.
28. Glumer C., Borch-Johnsen K., Colagiuri S. Can a screening programme for diabetes be applied to another population?. Diabet Med 2005, 22:1234-1238.
29. Makrilakis K., Liatis S., Grammatikou S., Perrea D., Katsilambros N. Implementation and effectiveness of the first community lifestyle intervention programme to prevent Type 2 diabetes in Greece. The Deplan study. Diabet Med 2010, 27:459-465.
30. Schwarz P.E., Lindstrom J., Kissimova-Scarbeck K., Szybinski Z., Barengo N.C., Peltonen M., et al. The European perspective of type 2 diabetes prevention: diabetes in Europe-prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Exp Clin Endocrinol Diabetes 2008, 116:167-172.
31. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
32. WHO: Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization. Department of Noncommunicable Disease Surveillance.1999.
33. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-421.
34. American Diabetes Association Screening for type 2 diabetes. Diabetes Care 2003, 26(Suppl 1):S21-S24.
35. Wareham N.J., Griffin S.J. Should we screen for type 2 diabetes? Evaluation against national screening committee criteria. BMJ 2001, 322:986-988.
36. Schwarz P.E., Li J., Lindstrom J., Tuomilehto J. Tools for predicting the risk of type 2 diabetes in daily practice. Horm Metab Res 2009, 41:86-97.
37. Bleeker S.E., Moll H.A., Steyerberg E.W., Donders A.R., Derksen-Lubsen G., Grobbee D.E., et al. External validation is necessary in prediction research: a clinical example. J Clin Epidemiol 2003, 56:826-832.
38. Vardavas C.I., Kafatos A.G. Smoking policy and prevalence in Greece: an overview. Eur J Public Health 2007, 17:211-213.
39. Haire-Joshu D., Glasgow R.E., Tibbs T.L. Smoking and diabetes. Diabetes Care 1999, 22:1887-1898.
40. Lindstrom J., Neumann A., Sheppard K.E., Gilis-Januszewska A., Greaves C.J., Handke U., et al. Take action to prevent diabetes - the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res 2010, 42(Suppl 1):S37-S55.